Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer cell immunity in the crosshairs: Worth the expense?

06.06.2016

It's time to say goodbye to ineffective and costly cancer treatments. Japanese scientists have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient.

Programmed-death ligand 1 (PD-L1) is a protein that tells the immune system not to kill a particular cell. Publishing in Nature, a recent study reports that genetic alterations affecting a part of the PD-L1 gene increases the production of the protein, allowing cancer cells to escape detection by the immune system.


Japanese scientists have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient. Publishing in Nature, the study reports that genetic alterations affecting a part of the PD-L1 gene increases the production of the protein, allowing cancer cells to escape detection by the immune system.

Credit: Kyoto University

"This is the first study to illustrate that a structural abnormality in the 3' untranslated region of the PD-L1 gene causes an abnormally high production of PD-L1 protein, consequently aiding cancer immune escape," says one of the lead authors, Keisuke Kataoka, at Kyoto University. "Our study suggests that whether or not a cancer has this particular abnormality could be a good indicator of its response to immune checkpoint inhibitor drugs."

Antibodies that target PD-L1 or its receptor PD-1 have shown remarkable therapeutic effects for many cancer patients, sometimes even for those who are terminally ill. Treatment using such antibodies is extremely expensive, however, and oncologists are keen to find a biomarker that can predict the effectiveness of these drugs for individual patients.

"We identified PD-L1 structural alterations affecting the 3' untranslated region of the PD-L1 gene in 27% of patients with adult T-cell leukemia/lymphoma by analyzing next-generation sequencing data," explains senior author Seishi Ogawa.

Prompted by this initial finding, the team searched for similar structural alterations in sequencing data from a total of 10,210 samples deposited in the Cancer Genome Atlas.

"Through this analysis, we found that such abnormalities were found in many common cancer types, including malignant lymphoma, as well as stomach and cervical cancers. We also generated human and mouse cells having a similar structural alteration using the CRISPR-Cas9 genome editing system, and confirmed that these cells actually showed an elevated expression of PD-L1 protein and were able to escape the immune attack." says Ogawa.

"To test the importance of such structural alteration as a genetic marker, a phase two clinical trial is ongoing at Kagoshima University and other institutions," adds Ogawa. "Once we confirm the significance of these genetic alterations, it'll be a game-changer for immunotherapy in cancer."

###

The paper "Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers" appeared May 23, 2016 in Nature, with doi: 10.1038/nature18294

Kyoto University is one of Japan and Asia's premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information please see: http://www.kyoto-u.ac.jp/en

Anna Ikarashi | EurekAlert!

Further reports about: CANCER genetic mechanism immune immune system lymphoma structural alteration

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>